目的 觀察康萊特注射液對(duì)晚期肝癌患者血清甲胎蛋白（AFP）的抑制作用和對(duì)患者體力狀況的影響。方法 選擇62例經(jīng)明確診斷的晚期肝癌患者，分為兩組，對(duì)照組給予保肝、生物反應(yīng)調(diào)節(jié)劑及支持對(duì)癥治療，治療組加用康萊特注射液100 mL靜脈滴注。結(jié)果 對(duì)照組治療后AFP受益率為54.84%，治療組為87.10%；兩組卡氏評(píng)分（KPS）受益率分別為61.29%、83.87%，兩者差異均有統(tǒng)計(jì)學(xué)意義（P＜0.05）。結(jié)論 康萊特注射液可明顯降低晚期肝癌患者外周血AFP水平，改善患者體力狀態(tài)，提高患者生活質(zhì)量。

Objective To observe the inhibition of Kanglaite Injection on serum alpha-fetoprotein (AFP) and the influence on physical condition of advanced hepatocellular carcinoma patients. Methods The 62 patients with advanced hepatocellular carcinoma were randomly divided into two groups. The control group was given liver-protected drugs and biological reaction regulator with the symptomatic treatment, while the treatment group was given 100 mL Kanglaite Injection via iv infusion. Results After treatment the benefit ratio of AFP in the control group was 54.84% and that in the treatment group was 87.10%. The benefit ratios of Karnofsky (KPS) score in the two groups were 61.29% and 83.87% both significant difference (P<0.05). Conclusion Kanglaite Injection could obviously decrease the AFP level in peripheral blood of advanced hepatocellular carcinoma patients and improve the physical state and life quality of the advanced hepatocellular carcinoma patients.